The heterogeneity of antipsychotic response in the treatment of schizophrenia

Psychological Medicine

Volumn 41, Issue 6, 2011, Pages 1291-1300

  Case, M ^a   Stauffer, V L ^a   Ascher Svanum, H ^b   Conley, R ^a   Kapur, S ^c   Kane, J M ^d   Kollack Walker, S ^a   Jacob, J ^a,b   Kinon, B J ^b  

^a Lilly USA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

Antipsychotic drugs; endophenotypes; growth mixture modeling; heterogeneity; response patterns; schizophrenia

Indexed keywords

BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOMETRY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; STATISTICS;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 79956001392     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291710001893     Document Type: Article

References (41)

1. Agid O, Kapur S, Arenovich T, Zipursky RB (2003). Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Archives of General Psychiatry 60, 1228-1235. (Pubitemid 37494076)
2. Aleman A, Kahn RS, Selten JP (2003). Sex differences in the risk of schizophrenia: evidence from meta-analysis. Archives of General Psychiatry 60, 565-571. (Pubitemid 36682313)
3. Ascher-Svanum H, Nyhius AW, Faris DE, Kinon BJ, Baker RW, Shekar A (2008). Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophrenia Bulletin 34, 1163-1171.
4. Ayuso-Gutierrez JL, del Rio Vega JM (1997). Factors influencing relapse in the long-term course of schizophrenia. Schizophrenia Research 28, 199-206. (Pubitemid 28055667)
5. Barnes TR (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry 154, 672-676. (Pubitemid 19154942)
6. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM (2003). Early prediction of antipsychotic response in schizophrenia. American Journal of Psychiatry 160, 2063-2065. (Pubitemid 39619650)
7. Garver DL, Holcomb JA, Christensen JD (2000). Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum. Journal of Clinical Psychiatry 61, 964-972. (Pubitemid 32058017)
8. Glick ID, Bossie CA, Alphs L, Canuso CM (2009). Onset and persistence of antipsychotic response in patients with schizophrenia. Journal of Clinical Psychopharmacology 29, 542-547.
9. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology, Revised. Publication ADM 76-338. US Department of Health, Education, and Welfare: Rockville, MD.
10. Haro JM, Novick D, Suarez D, Ochoa S, Roca M (2008). Predictors of the course of illness in outpatients with schizophrenia: a prospective three year study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 32, 1287-1292.
11. Harvey PD, Rabinowitz J, Eerdekens M, Davidson M (2005). Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. American Journal of Psychiatry 162, 1888-1895. (Pubitemid 41428618)
12. Heinrichs DW, Hanlon TE, Carpenter Jr. WT (1984). The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 10, 388-398.
13. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276. (Pubitemid 18039085)
14. Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L (2004). The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia Research 68, 283-297. (Pubitemid 38526150)
15. Kerwin RW, Osborne S (2000). Antipsychotic drugs. Medicine 28, 23-25.
16. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, Kane JM (2008). Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophrenia Research 102, 230-240.
17. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM (2010). Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 35, 581-590.
18. Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen A, Weiden P (1993). Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacology Bulletin 29, 309-314. (Pubitemid 23311541)
19. Kleinman L, Lieberman J, Dube S, Mohs R, Zhao Y, Kinon B, Carpenter W, Harvey PD, Green MF, Keefe RS, Frank L, Bowman L, Revicki DA (2009). Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. Schizophrenia Research 107, 275-285.
20. Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H, Woerner MG, Kane JM, Goldman D, Malhotra AK (2006). DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. American Journal of Psychiatry 163, 529-531. (Pubitemid 44469398)
21. Leucht S, Busch R, Kissling W, Kane JM (2007). Early prediction of antipsychotic nonresponse among patients with schizophrenia. Journal of Clinical Psychiatry 68, 352-360. (Pubitemid 46506798)
22. Levine SZ, Rabinowitz J (2010). Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophrenia Bulletin 36, 624-632.
23. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209-1223. (Pubitemid 41345943)
24. Lipkovich I, Deberdt W, Csernansky JG, Buckley P, Peuskens J, Kollack-Walker S, Rotelli M, Houston JP (2009). Defining 'good' and 'poor' outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach. Psychiatry Research 170, 161-167.
25. Liu-Seifert H, Adams D, Kinon BJ (2005). Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Medicine 3, 21.
26. Marques TR, Arenovich T, Agid O, Sajeev G, Muthén B, Chen LC, Kinon BJ, Kapur S (in press). The different trajectories of antipsychotic response: antipsychotics versus placebo. Psychological Medicine.
27. Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling RL, Thompson PA (1997). Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. American Journal of Psychiatry 154, 475-482. (Pubitemid 27147599)
28. Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005). Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 10, 79-104. (Pubitemid 40139590)
29. Moller HJ (2005). Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues. World Journal of Biological Psychiatry 6, 247-263.
30. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382-389. (Pubitemid 9136500)
31. Muthén B (2004). Latent variable analysis: growth mixture modeling and related techniques for longitudinal data. In Handbook of Quantitative Methodology for the Social Sciences (ed. D. Kaplan), pp. 345-368.
32. Sage Publications: Newbury Park, CA. Muthén B, Brown H (2009). Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling. Statistics in Medicine 28, 3363-3385.
33. Muthén B, Muthén L (2007). Mplus: Statistical Analysis with Latent Variables: User's Guide, 5th edn. Muthén and Muthén: Los Angeles, CA.
34. Naber D, Moritz S, Lambert M, Rajonk FG, Holzbach R, Mass R, Andresen B (2001). Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophrenia Research 50, 79-88. (Pubitemid 32510889)
35. Perkins DO (2002). Predictors of noncompliance in patients with schizophrenia. Journal of Clinical Psychiatry 63, 1121-1128. (Pubitemid 36084056)
36. Perkins DO (2005). Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. American Journal of Psychiatry 162, 1785-1804. (Pubitemid 41428609)
37. Rabinowitz J, Harvey PD, Eerdekens M, Davidson M (2006). Premorbid functioning and treatment response in recent-onset schizophrenia. British Journal of Psychiatry 189, 31-35. (Pubitemid 44023327)
38. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica (Suppl.) 212, 11-19.
39. Thieda P, Beard S, Richter A, Kane J (2003). An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatric Services 54, 508-516. (Pubitemid 36752981)
40. Ucok A, Polat A, Genc A, Cakir S, Tarun N (2004). Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia. Journal of Psychiatric Research 38, 163-168. (Pubitemid 38134457)
41. Uher R, Muthén B, Souery D, Mors O, Jaracz J, Placentino A, Petrovic A, Zobel A, Henigsberg N, Rietschel M, Aitchison KJ, Farmer A, McGuffin P (2010). Trajectories of change in depression severity during treatment with antidepressants. Psychological Medicine 40, 1367-1377.